GlassScriptPhysician profile
Anish Paudel
NPI 1295396380
$2,312.55
in general payments reported to CMS, 2019-2025
18 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2023: $453 · 2024: $781 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $582.64 | 2023-2025 | |
| Gilead Sciences, INC. | $358.19 | 2021-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $291.61 | 2024-2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.08 | 2021-2024 | Xifaxan |
| Janssen Biotech, INC. | $237.33 | 2024-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $182.61 | 2023-2024 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $90.77 | 2023 | Ocaliva |
| Ardelyx, INC. | $53.63 | 2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $47.38 | 2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $45.49 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $38.22 | 2025 | Wegovy |
| Pfizer INC. | $36.75 | 2025 | |
| Olympus America INC. | $19.43 | 2024 | Endoclot Phs |
| Recordati_rare_diseases_inc. | $19.22 | 2025 | Panhematin |
| Daiichi Sankyo INC. | $16.87 | 2025 | Injectafer |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $15.54 | 2025 | Uplizna |
| Phathom Pharmaceuticals, INC. | $14.49 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | Zerbaxa, Dificid, Zinplava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Paudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.